In Vivo CAR-T Development Service with AAV Vector Technology

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs' In Vivo CAR-T Development with AAV Vector Technology addresses the critical industry challenges of insertional mutagenesis from random integration, transient therapeutic persistence, and the exorbitant costs of ex vivo manufacturing. Our solution leverages a novel non-viral vector system, enabling precise, site-directed CAR gene integration for an enhanced safety profile. Coupled with advanced capsid engineering to mitigate immunogenicity, our platform facilitates the development of potent and durable CAR-T therapies, thereby de-risking and accelerating your development process.

Introduction

Adeno-associated virus (AAV) vector technology is a leading gene delivery platform renowned for its high transduction efficiency and favorable safety profile. This technology can be innovatively applied to in vivo CAR-T development by enabling direct T cell engineering within the patient, while co-administering AAV-specific CAR Tregs to locally suppress anti-vector immunity, thereby promoting durable transgene expression and overcoming a major clinical hurdle.

Fig.1 Establishment of a manufacturing process for AAV-targeting CAR Tregs. (Creative Biolabs Original) Fig.1 Engineering a platform for AAV-specific CAR-Treg development.

In Vivo CAR-T Development with AAV Vector Technology at Creative Biolabs

Creative Biolabs' In Vivo CAR-T Development with AAV Vector Technology facilitates the direct generation of functional CAR-T cells within the patient, thereby circumventing the need for extensive ex vivo manipulation. Our approach is distinguished by site-specific transgene integration into the AAVS1 safe harbor for enhanced genomic safety, coupled with engineered capsids for precise cellular targeting, directly addressing the pivotal challenges of immunogenicity and therapeutic persistence.

What We Can Offer

We offer a comprehensive suite of advanced AAV vector engineering solutions for in vivo CAR-T development. Our expertise spans tailored capsid design for precise T cell targeting, optimized genomic architectures for rapid and specific transgene expression, and integrated regulatory elements to enhance both safety and controllability of the therapeutic product.

Featured services of in vivo CAR-T development with AAV vector technology at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Specific CAR Sequence (ScFv, hinge, transmembrane, and signaling domains).
Target Antigen and associated cell line for functional testing.
Desired AAV serotype or pre-validated engineered capsid.

Key Steps:

Workflow of in vivo CAR-T development with AAV vector technology at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Comprehensive Vector Characterization Report (titer, purity, and AAVS1 integration percentage).
Detailed Efficacy and Safety Data Package.
Final Master Cell Bank of the optimized T cell line.

Key Advantages

Unprecedented Safety Profile: Leveraging the AAVS1 genomic safe harbor for integration, virtually eliminating insertional mutagenesis risk—a critical, high-impact advantage for securing a successful Investigational New Drug (IND) filing safety package.
Precision Targeting System: Implementation of Creative Biolabs' proprietary Triple-Layer Targeting (Transductional, Transcriptional, Post-Transcriptional) strategies for rigorous control over CAR expression, maximizing therapeutic efficacy and minimizing off-target toxicity in healthy tissues.
Redosing & Durability Solutions: Advanced strategies, including the engineering and deployment of AAV-CAR Regulatory T cells (AAV-CAR Tregs), to actively suppress anti-AAV immunity, opening the path for successful therapeutic redosing and extended CAR-T persistence.

FAQ

How does your approach compare to using traditional lentiviruses for CAR-T?

Traditional lentiviruses integrate randomly, carrying the inherent risk of insertional mutagenesis. Our AAV-derived vector system ensures the CAR gene is preferentially integrated into the safe and transcriptionally active AAVS1 locus. This targeted integration offers a superior safety profile for your clinical pipeline. Contact us to review the comprehensive safety data.

What information is needed to begin a project, and how long does the process take?

We primarily require your optimized CAR sequence and target antigen. The typical timeframe ranges from 14 to 26 weeks, depending on the complexity of the CAR design and the required level of preclinical in vivo validation. Please reach out to our team to discuss your specific target and receive a customized project timeline.

Why Choose Us?

Creative Biolabs pioneers in vivo CAR-T development by uniquely integrating AAV vector precision with advanced immunomodulation. Our platform ensures site-specific CAR integration at the AAVS1 safe harbor for enhanced genomic safety, employs multi-layer targeting to restrict CAR expression to T cells, and introduces AAV-CAR Tregs to enable redosing. This comprehensive approach directly addresses the critical challenges of safety, specificity, and durability in next-generation cell therapy.

Customer Reviews

"Using Creative Biolabs' In Vivo CAR-T Development with AAV Vector Technology in our research has significantly improved the confidence in our preclinical safety data. The AAVS1-targeted integration data was essential for de-risking our candidate compared to the random-integration approach we previously used." Dr. S***n K.

"Creative Biolabs' In Vivo CAR-T Development with AAV Vector Technology has significantly facilitated our exploration of redosing. Their AAV-CAR Treg strategy effectively suppressed the immune response to the vector capsid, allowing us to maintain high levels of transgene expression over a longer period than previously thought possible." P***r M.

"The use of the AAV-derived CELiD vector provided by Creative Biolabs' In Vivo CAR-T Development with AAV Vector Technology made our vector manufacturing easier and faster than preparing traditional viral vectors, leading to a substantial reduction in batch-to-batch variability and overall cost per dose." D***a W.

How to contact us?

We provide a pioneering platform for next-generation CAR-T cells, leveraging AAV vector technology and safe harbor integration to de-risk and streamline the clinical development pathway. Our integrated strategy maximizes the success probability of your therapeutic candidates.

Reach out to us to initiate a conversation.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.